These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38901515)

  • 1. In silico screening and in vivo experimental validation of 15-PGDH inhibitors from traditional Chinese medicine promoting liver regeneration.
    Feng C; Qiao C; Ji W; Pang H; Wang L; Feng Q; Ge Y; Rui M
    Int J Biol Macromol; 2024 Aug; 274(Pt 1):133263. PubMed ID: 38901515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.
    Zhang Y; Desai A; Yang SY; Bae KB; Antczak MI; Fink SP; Tiwari S; Willis JE; Williams NS; Dawson DM; Wald D; Chen WD; Wang Z; Kasturi L; Larusch GA; He L; Cominelli F; Di Martino L; Djuric Z; Milne GL; Chance M; Sanabria J; Dealwis C; Mikkola D; Naidoo J; Wei S; Tai HH; Gerson SL; Ready JM; Posner B; Willson JK; Markowitz SD
    Science; 2015 Jun; 348(6240):aaa2340. PubMed ID: 26068857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding human 15-hydroxyprostaglandin dehydrogenase binding with NAD+ and PGE2 by homology modeling, docking and molecular dynamics simulation.
    Hamza A; Cho H; Tai HH; Zhan CG
    Bioorg Med Chem; 2005 Jul; 13(14):4544-51. PubMed ID: 15908215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of 15-PGDH prevents ischemic renal injury by the PGE
    Kim HJ; Kim SH; Kim M; Baik H; Park SJ; Kang MS; Kim DH; Kim BW; Markowitz SD; Bae KB
    Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1054-F1066. PubMed ID: 33135478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) prevents lipopolysaccharide (LPS)-induced acute liver injury.
    Yao L; Chen W; Song K; Han C; Gandhi CR; Lim K; Wu T
    PLoS One; 2017; 12(4):e0176106. PubMed ID: 28423012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair.
    Antczak MI; Zhang Y; Wang C; Doran J; Naidoo J; Voruganti S; Williams NS; Markowitz SD; Ready JM
    J Med Chem; 2017 May; 60(9):3979-4001. PubMed ID: 28398755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
    Hu B; Toda K; Wang X; Antczak MI; Smith J; Geboers S; Nishikawa G; Li H; Dawson D; Fink S; Desai AB; Williams NS; Markowitz SD; Ready JM
    J Med Chem; 2022 Nov; 65(22):15327-15343. PubMed ID: 36322935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue.
    Bärnthaler T; Theiler A; Zabini D; Trautmann S; Stacher-Priehse E; Lanz I; Klepetko W; Sinn K; Flick H; Scheidl S; Thomas D; Olschewski H; Kwapiszewska G; Schuligoi R; Heinemann A
    J Allergy Clin Immunol; 2020 Mar; 145(3):818-833.e11. PubMed ID: 31812575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.
    Niesen FH; Schultz L; Jadhav A; Bhatia C; Guo K; Maloney DJ; Pilka ES; Wang M; Oppermann U; Heightman TD; Simeonov A
    PLoS One; 2010 Nov; 5(11):e13719. PubMed ID: 21072165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis.
    Smith JNP; Witkin MD; Jogasuria AP; Christo KF; Raffay TM; Markowitz SD; Desai AB
    Sci Rep; 2020 Jul; 10(1):11657. PubMed ID: 32669620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wound healing effects of new 15-hydroxyprostaglandin dehydrogenase inhibitors.
    Piao YL; Seo SY; Lim SC; Cho H
    Prostaglandins Leukot Essent Fatty Acids; 2014 Dec; 91(6):325-32. PubMed ID: 25458900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin dehydrogenase is a target for successful induction of cervical ripening.
    Kishore AH; Liang H; Kanchwala M; Xing C; Ganesh T; Akgul Y; Posner B; Ready JM; Markowitz SD; Word RA
    Proc Natl Acad Sci U S A; 2017 Aug; 114(31):E6427-E6436. PubMed ID: 28716915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional differences in prostaglandin E₂ metabolism in human colorectal cancer liver metastases.
    Young AL; Chalmers CR; Hawcroft G; Perry SL; Treanor D; Toogood GJ; Jones PF; Hull MA
    BMC Cancer; 2013 Feb; 13():92. PubMed ID: 23442768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.
    Duveau DY; Yasgar A; Wang Y; Hu X; Kouznetsova J; Brimacombe KR; Jadhav A; Simeonov A; Thomas CJ; Maloney DJ
    Bioorg Med Chem Lett; 2014 Jan; 24(2):630-5. PubMed ID: 24360556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors.
    Mallipeddi PL; Zhang Y; Li H; Markowitz SD; Posner B
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in studies of 15-PGDH as a key enzyme for the degradation of prostaglandins.
    Sun CC; Zhou ZQ; Yang D; Chen ZL; Zhou YY; Wen W; Feng C; Zheng L; Peng XY; Tang CF
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108176. PubMed ID: 34655851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.
    Kochel TJ; Fulton AM
    Prostaglandins Other Lipid Mediat; 2015; 116-117():99-103. PubMed ID: 25433169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.
    Lu D; Han C; Wu T
    J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E2 alterations during sepsis are partially mediated by endotoxin-induced inhibition of prostaglandin 15-hydroxydehydrogenase.
    Hahn EL; Clancy KD; Tai HH; Ricken JD; He LK; Gamelli RL
    J Trauma; 1998 May; 44(5):777-81; discussion 781-2. PubMed ID: 9603077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of the intracellular levels of prostaglandin E₂ through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing.
    Choi D; Piao YL; Wu Y; Cho H
    Bioorg Med Chem; 2013 Aug; 21(15):4477-84. PubMed ID: 23791868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.